Journal of Immunology Research / 2015 / Article / Tab 2

Clinical Study

Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients

Table 2

Adverse events during the PPV ().

EventNumber
Grade 1Grade 2Grade 3Grade 4Grade 5Total (%)

Injection site skin reaction15420021 (50%)
Blood/bone marrow
 Anemia7400011 (26%)
 Lymphopenia9100010 (24%)
 Neutropenia02000 2 (5%)
 Thrombocytopenia70000 7 (17%)
 Leukopenia31000 4 (10%)
Laboratory
 AST increase4640014 (33%)
 ALT increase10120013 (31%)
 ALP increase9200011 (26%)
 GGT increase7320012 (29%)
 Bilirubin increase22000 4 (10%)
 Creatinine increase21000 3 (7%)
Gastrointestinal disorders
 Anorexia53000 8 (19%)
 Abdominal distension20000 2 (5%)
 Ascites21100 4 (10%)
 Constipation02000 2 (5%)
Edema limbs20000 2 (5%)
Fever50000 5 (12%)
Malaise30000 3 (7%)
Pain13200 6 (14%)
Pruritus20000 2 (5%)
Eruption21000 3 (7%)
Urinary incontinence01000 1 (2%)
Pleural infection00001 1 (2%)
Hypertension00100 1 (2%)
Insomnia01000 1 (2%)